(Q50594258)

16 March 2018

title

Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. (English)

1 reference

16 March 2018

0 references

0 references

0 references

Rajiv Radhakrishnan

7

0 references

author name string

Mohini Ranganathan

1

1 reference

16 March 2018

Michelle Carbuto

2

1 reference

16 March 2018

Gabriel Braley

3

1 reference

16 March 2018

Jaqueline Elander

4

1 reference

16 March 2018

Edward Perry

5

1 reference

16 March 2018

Brian Pittman

6

1 reference

16 March 2018

Richard A Sewell

8

1 reference

16 March 2018

Deepak C D'Souza

9

1 reference

16 March 2018

publication date

16 January 2012

1 reference

16 March 2018

The International Journal of Neuropsychopharmacology

published in

1 reference

16 March 2018

volume

15

1 reference

16 March 2018

page(s)

1251-1264

1 reference

16 March 2018

issue

9

1 reference

16 March 2018

CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats.

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Functional interaction between opioid and cannabinoid receptors in drug self-administration.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Gender differences in proenkephalin gene expression response to delta9-tetrahydrocannabinol in the hypothalamus of the rat

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Opioid antagonism enhances marijuana's effects in heavy marijuana smokers

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Pharmacological and biochemical interactions between opioids and cannabinoids.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Clinical effects and plasma levels of ?9-Tetrahydrocannabinol (?9-THC) in heavy and light users of cannabis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Interaction between naltrexone and oral THC in heavy marijuana smokers.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI)

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Addiction Research Center Inventory (ARCI): development of a general drug estimation scale

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Nicotine and endogenous opioids: Neurochemical and pharmacological evidence

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Pharmacokinetics and pharmacodynamics of cannabinoids

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Antinociceptive, subjective and behavioral effects of smoked marijuana in humans.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

https://api.crossref.org/works/10.1017%2FS1461145711001830

1 reference

7 January 2021

Cannabinoids and reward: interactions with the opioid system.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Synergistic interactions of endogenous opioids and cannabinoid systems

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

THC-methadone and THC-naltrexone interactions on discrimination, antinociception, and locomotion in rats.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Molecular and cellular basis of cannabinoid and opioid interactions.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

The development and initial validation of a questionnaire on smoking urges

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Effects of naltrexone on pharmacodynamics and pharmacokinetics of intravenously administered morphine in the rat

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by Δ9-THC in the rat

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711001830

7 January 2021

10.1017/S1461145711001830

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

22243563

1 reference

16 March 2018